Pharmafile Logo

The value: why localisation pays off across global trials

Strong localisation reduces trial friction, supports site teams, improves participant understanding and helps global studies run more smoothly, fairly and efficiently.

- PMLiVE

In our first two articles, we looked at where translation falls short and what good localisation actually looks like. Now we come to the part that affects timelines, budgets and trial delivery: the operational impact of getting localisation wrong.

Poor localisation rarely announces itself. It shows up quietly, in extra questions, slower processes, and avoidable rework. Strong localisation does the opposite. It keeps trials moving and helps sites focus on participants.

Where poor localisation creates friction

When materials don’t quite land, the effects ripple across sites and regions. Teams often see more site queries, with participants asking staff to explain content that should already be clear. Consent and onboarding slow down as confusion delays decisions. And when materials need revising market by market after launch, rework quickly builds.

These aren’t isolated problems. In our recent report The Site Factor, 27% of European respondents cited delays in receiving sponsor materials as their biggest barrier to enrolling participants. Just 24% of site teams say they use sponsor-provided materials, while others supplement them with their own materials or report having no participant-facing materials at all.

The hidden cost of fixing content late

Fixing localisation late is far more expensive than getting it right early. A single change to a master document can trigger updates across every language version, requiring fresh review, approval and redistribution. When amendments arrive out of sequence, sites are left unsure what to apply and when.

That uncertainty has a cost. It pulls site staff away from participants, adds review cycles, and risks inconsistency across regions. The later you spot the gap, the wider it spreads.

How strong localisation supports smoother delivery

Done well, localisation removes friction before it starts. Content arrives ready to use, reducing the burden on site teams to interpret, adapt or explain materials that participants find difficult to understand.

Across a trial, those benefits add up: fewer clarification queries for site staff, more consistent understanding across markets, smoother consent and onboarding processes, and less need for local workarounds or supplementary materials.

When participants understand what’s being asked of them, they’re more likely to engage and stay. And a better participant experience links directly to greater study completion.

Localisation, risk and diversity

Localisation isn’t just about clarity. It’s about reach. If your materials only work for some communities, your trial only reaches those communities. That limits diversity and skews representation, ultimately affecting the quality of the data generated.

Strong localisation helps you recruit fairly across regions and cultures. It reduces protocol misunderstandings, supports adherence, and lowers the risk of avoidable delays. In short, it makes trials more efficient and more representative.

Bringing the series together

Across these three articles, one idea has stayed constant. While translation carries the language, localisation carries the meaning.

That difference shapes how participants interpret, trust and engage with your trial. Treat localisation as a core part of your trial communication strategy, not a final production step, and you’ll see the value in smoother delivery, stronger engagement and better outcomes for everyone involved.

And that’s a goal worth building towards.

This content was provided by Cuttsy + Cuttsy

Company Details

 Latest Content from  Cuttsy + Cuttsy 

How is generative AI transforming clinical trials?

Discover how generative AI is revolutionising clinical trials, from enhancing patient recruitment to improving data analysis.

Content for all – how to connect with neurodiverse audiences

Discover essential strategies for crafting inclusive and accessible written content tailored for neurodivergent readers.

Cuttsy+Cuttsy launches ccura: AI powered, always human

Cuttsy+Cuttsy introduces ccura, an AI-powered healthcare communications platform that blends technology with human expertise to enhance collaboration, streamline workflows, and deliver patient-focused, high-quality solutions with security and compliance at its…

Two Sides of the Same Coin: Patient Engagement vs Patient Involvement

Unpack the difference between patient engagement and patient involvement.

Cuttsy+Cuttsy achieves Platinum accreditation from Investors in People

Cuttsy+Cuttsy is proud to have achieved a Platinum accreditation from Investors in People, placing them among the top 2% of organisations assessed globally.

Cuttsy+Cuttsy awarded Gold EcoVadis sustainability rating

Cuttsy+Cuttsy proudly announces their Gold Medal achievement from EcoVadis for 2024, placing them among the top 5% of companies assessed and within the 97th percentile, a testament to their unwavering…

Age is not just a number when it comes to clinical trials

In this blog we look at the critical underrepresentation of older adults in clinical trials, emphasising the need for inclusive trial designs and targeted strategies to ensure safe and effective…

How to boost clinical trial access and make patients health-empowered

Clinical research is becoming more patient-centric, but there’s still more that needs to be done to make clinical trials available to everyone. This could include wider participation.

Closing the loop: Why clinical trial results matter to participants

Discover why sharing clinical trial results with participants is crucial for respect, informed health decisions, and fostering strong researcher-participant partnerships.

Unveiling the truth: A journey into women’s representation in clinical trials

We explore the historical exclusion of women from clinical trials, its consequences on medical research and treatment efficacy and the ongoing efforts to ensure their representation.